Ibrutinib Versus FCR: A "Paradigm Shift" for Younger Patients With Treatment-Naïve CLL
Cancers | Free Full-Text | First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era
J&J, AbbVie's Imbruvica pads CLL lead with FDA green light in younger patients | Fierce Pharma
Ibrutinib in Combination with Rituximab or Lenalidomide/Rituximab for Untreated FL | Research To Practice
Treatment Initiation and Selection in Newly Diagnosed CLL - ppt download
Cancers | Free Full-Text | Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option
Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia - ScienceDirect
A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma | Haematologica
A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia | Trials | Full Text
Ibrutinib Therapy for CLL: Long-Term Data
Rationale Objective Study Schema Treatment Plan Eligibility Criteria Rationale Follow Up
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL | NEJM
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results | Blood Cancer Journal
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL | NEJM
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia | NEJM
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
ADVANCES IN TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
ALLIANCE - Progression-Free Survival | IMBRUVICA® (ibrutinib) HCP
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Leukemia
Managing CLL With BTK Inhibitors - ppt download
IVO vs IO Phase 3 Trial of the Impact of Adding Venetoclax to Ibrutinib and Obinutuzumab in CLL
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
